EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer

Ítems similars

• EGFR T790M Mutation as a Possible Target for Immunotherapy; Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the EGFR T790M Mutation
  per: Yamada, Teppei, et al.
  Publicat: (2013)
• Humoral Immune Responses to EGFR-Derived Peptides Predict Progression-Free and Overall Survival of Non-Small Cell Lung Cancer Patients Receiving Gefitinib
  per: Azuma, Koichi, et al.
  Publicat: (2014)
• Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients
  per: Matsuo, Norikazu, et al.
  Publicat: (2016)
• Immunotherapy Rechallenge of Advanced NSCLC with Acquired EGFR T790M Mutation after EGFR-TKI Therapy: A Case Report
  per: Hu Y, et al.
  Publicat: (2025-11-01)
• The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma
  per: Zhang, Qiuyi, et al.
  Publicat: (2016)